Actively Recruiting
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Led by Dana-Farber Cancer Institute · Updated on 2025-12-10
1000
Participants Needed
6
Research Sites
282 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
B
Beth Israel Deaconess Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
CONDITIONS
Official Title
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Non-tobacco using (currently)
- Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx
- Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean for Aims 1 and 2
- Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish for Aim 3
- For ages 50 through 80: meet above criteria
- For ages 40 through 49: meet above criteria and have either family history of EGFR positive lung cancer L858R or exon 19 deletions, personal history of remote cancer not lung or thoracic malignancies resolved over 5 years ago, history of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis, or lung cancer symptoms in the past month (hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea)
- Exclude individuals with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, or productive cough with green or yellow sputum
You will not qualify if you...
- Chest CT scan in the last 3 years or expected during enrollment
- Current cancer or history of cancer within last 5 years excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ
- More than 400 lifetime cigarettes (20 packs) of smoking or tobacco use
- Unable to provide informed consent
- Under 40 years of age
- Prisoners
- Pregnant women
- Personal diagnosis of lung cancer
- Unable to comply with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
3
Massachusetts General Hospital
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
4
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts, United States, 02135
Not Yet Recruiting
5
Dana-Farber Cancer Instiute Merrimack Valley
Methuen, Massachusetts, United States, 01844
Not Yet Recruiting
6
Dana-Farber Cancer Institute South Shore
South Weymouth, Massachusetts, United States, 02190
Not Yet Recruiting
Research Team
J
Jennifer Lee
CONTACT
F
Fernando Pacheco
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here